University of Vermont

The College of Arts and Sciences

Department of Psychological Science

Stacey Sigmon

Human Behavioral Pharmacology

Stacey Sigmon

Stacey Sigmon
Research Associate Professor of Psychology
Research Associate Professor of Psychiatry

  • B.A. University of North Carolina at Chapel Hill, 1995
  • M.A. University of Vermont, 1999
  • Ph.D. University of Vermont, 2002
  • NIH Postdoctoral Fellowship at Johns Hopkins University School of Medicine
  • C.V. (PDF)
Phone: (802) 656-8714
Room: FAHC-UHC Room 1415


Director, The Chittenden Clinic


Faculty, Substance Abuse Treatment Center

Faculty, Human Behavioral Pharmacology Laboratory

Faculty, Behavioral Pharmacology of Drug Dependence Training Program


Behavioral and pharmacological treatment of opioid dependence; Novel formulations of pharmacotherapies for opioid dependence; Smoking cessation among opioid-dependent patients using a behavioral approach; Laboratory models for understanding the interactions between stimulant medications, including nicotine, cocaine, d-amphetamine and methylphenidate; Behavioral treatments of substance use/abuse among individuals with serious mental illness.


Vermont Center on Behavior and Health: The Vermont Center on Behavior and Health (VCBH) is an interdisciplinary center of research excellence committed to investigating relationships between personal behavior patterns (i.e., lifestyle) and risk for chronic disease and premature death.

Human Behavioral Pharmacology Laboratory (HBPL): This facility of 6,000 sq. ft., is located adjacent to the University of Vermont (UVM) campus in Burlington and is the site for laboratory research in drug self-administration, drug discrimination, and the direct effects of drugs and for treatment studies for smoking cessation.

Substance Abuse Treatment Center (SATC): This facility of 2,900 sq. ft., is also located adjacent to the UVM campus, and is our site for the development and testing of scientifically-based behavioral and pharmacological treatments for cocaine and opioid dependence as well as smoking cessation for pregnant women. For addtional information on the Substance Abuse Treatment Center3.

Representative Publications

  • Dunn, K.E., Sigmon, S.C., Reimann, E., Heil, S.H., & Higgins, S.T. (2009). Effects of smoking cessation on illicit drug use among opioid maintenance patients. Journal of Drug Issues, Vol. 39(2), 313-328.
  • Sigmon, S.C., Herning, R.I., Better, W., Cadet, J.L., & Griffiths, R.R. (2009). Caffeine withdrawal, acute effects, tolerance, and absence of net beneficial effects of chronic administration: Cerebral blood flow velocity, quantitative EEG and subjective effects. Psychopharmacology, 204, 573-585.
  • Sigmon, S.C., Dunn, K.E., Badger, G.J., Heil, S.H., & Higgins, S.T. (2009). Brief buprenorphine detoxification for the treatment of prescription opioid dependence: A pilot study. Addictive Behaviors, 34, 304-311.
  • Dunn, K.E., Sigmon, S.C., Thomas, C.S., Heil, S.H. & Higgins, S.T. (2008). Voucher-based contingent reinforcement of smoking abstinence among methadone-maintained patients: A pilot study. Journal of Applied Behavior Analysis, 41, 527-538.
  • Dunn, K.E., Sigmon, S.C., McGee, M.R., Heil, S.H., & Higgins, S.T. (2008). Evaluation of ongoing oxycodone abuse among methadone-maintained patients. Journal of Substance Abuse Treatment, 35, 451-456.
  • Sigmon, S.C. (2006). Characterizing the emerging population of prescription opioid abusers. The American Journal on Addictions, 15 (3), 208-212.

Faculty and Staff Directory